Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada.
Community Guidelines: https://rb.gy/07ltg3
Company Details
- Employees
- 460
- Founded
- -
- Address
- 400 Fifth Avenue, 210,united States
- Phone
- 510) 745-1700
- in****@****lyx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ardelyx.com
- Keywords
- / US….
- HQ
- Waltham, MA
Ardelyx, Inc. Questions
Ardelyx, Inc.'s helpline number is 510) 745-1700
Ardelyx, Inc.'s website is ardelyx.com
Ardelyx, Inc.'s LinkedIn profile is https://www.linkedin.com/company/ardelyx-inc-
Ardelyx, Inc. has
460 employees.
View email and phone details for 460
employees at Ardelyx, Inc..
Ardelyx, Inc.'s industry is
Biotechnology Research
Ardelyx, Inc.'s top competitors are
Apellis Pharmaceuticals,
Beigene,
Alnylam Pharmaceuticals,
Bridgebio,
Alkermes,
Biomarin Pharmaceutical Inc.,
Argenx,
Akebia Therapeutics,
Agios Pharmaceuticals,
Madrigal Pharmaceuticals.
Ardelyx, Inc.'s support email address is info@ardelyx.com
Ardelyx, Inc.'s categories are Biotechnology Research
Ardelyx, Inc.'s founding year is 2007
